Effects of the Human Immunodeficiency Virus (HIV) Proteinase Inhibitors Saquinavir and Indinavir on In Vitro Activities of Secreted Aspartyl Proteinases of
            <i>Candida albicans</i>
            Isolates from HIV-Infected Patients

Körting, Hans Christian; Schaller, Martin; Eder, Gabriele; Hamm, Gerald; Böhmer, Ursula; Hube, Bernhard

doi:10.1128/aac.43.8.2038

Cited by 132 publications

(78 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For several drugs, evidence of in vitro effectiveness has been followed by direct demonstration of clinical activity [17][18][19]. Similar effects have been shown with Candida [8,40,41]. PIs are structurally related synthetic proteins with amino acid sequences based on those recognized and cleaved by HIV proteases, with strong activity in vitro (at concentrations of 2-60 nM).…”

Section: Discussionmentioning

confidence: 81%

In Vitro Activity of Human Immunodeficiency Virus Protease Inhibitors againstPneumocystis carinii

et al. 2000

View full text Add to dashboard Cite

Since 1996, the introduction of protease inhibitors (PIs) has led to a dramatic decrease of human immunodeficiency virus-related Pneumocystis carinii pneumonia. This effect is clearly due, in large part, to the induction of immune reconstitution by highly active antiretroviral therapy (HAART). However, it is conceivable that PIs had other beneficial effects, including direct activity against Pneumocystis. In this study, the occurrence of specific aspartyl proteases in Pneumocystis is described. These protease targets seemed to be affected in vitro by antiretroviral PIs. These data suggest intriguing implications for the possible antipneumocystis benefit of receiving indinavir, ritonavir, nelfinavir, or saquinavir during HAART.

show abstract

Section: Discussionmentioning

confidence: 81%

In Vitro Activity of Human Immunodeficiency Virus Protease Inhibitors againstPneumocystis carinii

et al. 2000

View full text Add to dashboard Cite

show abstract

“…45 The HIV proteinase inhibitors, such as saquinavir and indinavir, which already showed potency in the cure of candidiasis, can be carefully selected and considered as potential candidates for anticandidal virulence agents. 46,47 Virulence Phospholipases are another major C. albicans secreted enzymes contributed to invasiveness during infections.…”

Section: Anti-secreted Hydrolytic Enzymesmentioning

confidence: 99%

Synergistic combinations of antifungals and anti-virulence agents to fight againstCandida albicans

et al. 2015

View full text Add to dashboard Cite

Candida albicans, one of the pathogenic Candida species, causes high mortality rate in immunocompromised and high-risk surgical patients. In the last decade, only one new class of antifungal drug echinocandin was applied. The increased therapy failures, such as the one caused by multi-drug resistance, demand innovative strategies for new effective antifungal drugs. Synergistic combinations of antifungals and anti-virulence agents highlight the pragmatic strategy to reduce the development of drug resistant and potentially repurpose known antifungals, which bypass the costly and time-consuming pipeline of new drug development. Anti-virulence and synergistic combination provide new options for antifungal drug discovery by counteracting the difficulty or failure of traditional therapy for fungal infections.

show abstract

“…5; [42]). Die HIVProteinaseinhibitoren Saquinavir und Indinavir hemmen sezernierte Aspartatproteinase von Candida albicans dosisabhän-gig in vitro in Konzentrationen,wie sie bei der Behandlung der HIV-Infektion beim Menschen erreicht werden [29].…”

Section: Pathogeneseunclassified

Neue Entwicklungen in der medizinischen Mykologie

Körting

Schaller

2001

Der Hautarzt

View full text Add to dashboard Cite

Not only have the systemic mycoses clearly increased in number but also mycoses of the skin are more common than presumed in the past. Today onychomycosis is found in up to 10% of human beings. Onychomycosis can compromise quality of life markedly. Common tinea pedis is one of the most important risk factors for erysipelas of the lower legs. The clinical presentation of oral candidosis in HIV-infected patients is changing; Candida dubliniensis has been identified as another important causative microorganism. Onychomycosis today in most cases can be cured using terbinafine or itraconazole. When choosing the ideal drug in a given case, both the benefit risk ratio and the benefit cost ratio have to be taken into account. Liposomally encapsulated amphotericin B represents a major breakthrough in the treatment of systemic mycoses or fever of unknown origin. The same applies to liposomally encapsulated econazole with respect to tinea pedis. In regard to the pathogenesis of Candida infections the family of secreted aspartic proteinases plays a major role as a virulence factor and possible future target for antimycotic treatment.

show abstract

Effects of the Human Immunodeficiency Virus (HIV) Proteinase Inhibitors Saquinavir and Indinavir on In Vitro Activities of Secreted Aspartyl Proteinases of Candida albicans Isolates from HIV-Infected Patients

Cited by 132 publications

References 36 publications

In Vitro Activity of Human Immunodeficiency Virus Protease Inhibitors againstPneumocystis carinii

In Vitro Activity of Human Immunodeficiency Virus Protease Inhibitors againstPneumocystis carinii

Synergistic combinations of antifungals and anti-virulence agents to fight againstCandida albicans

Neue Entwicklungen in der medizinischen Mykologie

Contact Info

Product

Resources

About